Loading company…
South San Francisco-based biopharmaceutical company using its Tailored Covalency platform to develop oral small molecules.
Founded in 2008 and based in California, US, Principia BioPharma Inc. uses its Tailored Covalency platform to design and develop small-molecule oral therapies for patients with cancer, autoimmune and inflammatory diseases. The directory lists it at Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in